Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report)’s stock price dropped 11.5% on Tuesday. The stock traded as low as C$13.94 and last traded at C$13.94. Approximately 100 shares changed hands during trading, a decline of 94% from the average session volume of 1,700 shares. The stock had previously closed at C$15.76.
Neuren Pharmaceuticals Stock Performance
The stock’s fifty day simple moving average is C$15.14 and its 200-day simple moving average is C$11.32.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.
The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.
Further Reading
- Five stocks we like better than Neuren Pharmaceuticals
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
